DMU-212 against EGFR-mutant non-small cell lung cancer via AMPK/PI3K/Erk signaling pathway

DMU-212 against EGFR-mutant non-small cell lung cancer via AMPK/PI3K/Erk signaling pathway

Although some important advances have been achieved in clinical and diagnosis in the past few years, the management of non-small cell lung cancer (NSCLC) is ultimately dissatisfactory due to the low overall cure and survival rates. Epidermal growth factor (EGFR) has been recognized as a carcinogenic...

תיאור מלא

מידע ביבליוגרפי
Main Authors:	Xiao-Ping Zhao, Xiao-Li Zheng, Min Huang, Ya-Jia Xie, Xiao-Wen Nie, Ali Adnan Nasim, Xiao-Jun Yao, Xing-Xing Fan
פורמט:	Article
שפה:	English
יצא לאור:	Elsevier 2023-05-01
סדרה:	Heliyon
נושאים:	EGFR mutation NSCLC Lung cancer DMU-212 EGFR-AMPK pathway
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S2405844023030190

פריטים דומים

In Vivo Metabolite Profiling of DMU-212 in Apc<sup>Min/+</sup> Mice Using UHPLC-Q/Orbitrap/LTQ MS
מאת: Jing Li, et al.
יצא לאור: (2023-04-01)

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
מאת: Meng-Xia Li, et al.
יצא לאור: (2017-04-01)

AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
מאת: Hua Ye, et al.
יצא לאור: (2020-07-01)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
מאת: Li Liu, et al.
יצא לאור: (2021-10-01)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
מאת: Kejing Tang, et al.
יצא לאור: (2019-02-01)

EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists
מאת: Stephen V. Liu, et al.
יצא לאור: (2023-09-01)

Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis
מאת: Di Hu, et al.
יצא לאור: (2023-06-01)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
מאת: Chien-Chung Lin, et al.
יצא לאור: (2021-02-01)

EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis
מאת: Jeng-Shiuan Tsai, et al.
יצא לאור: (2021-09-01)

Efficacy and Safety of Chemotherapy or EGFR‐TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
מאת: Chen Liao, et al.
יצא לאור: (2025-01-01)

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
מאת: Jae Cheol Lee, et al.
יצא לאור: (2021-05-01)

Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSCLC patient: a case report and literature review
מאת: Xin Pan, et al.
יצא לאור: (2024-08-01)

Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know
מאת: Alexander Meisel
יצא לאור: (2020-03-01)

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
מאת: Yongkang Bai, et al.
יצא לאור: (2023-04-01)

Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway
מאת: Ling Li, et al.
יצא לאור: (2020-09-01)

A Visual Analysis of the Research Dynamics in Resistance to EGFR Inhibitors for NSCLC
מאת: Shao J, et al.
יצא לאור: (2024-06-01)

Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC
מאת: William Tompkins, MD, et al.
יצא לאור: (2024-08-01)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
מאת: Kate S, et al.
יצא לאור: (2019-01-01)

Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways
מאת: Yanjun Huang, et al.
יצא לאור: (2018-07-01)

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations
מאת: Tia Cheunkarndee, BA, et al.
יצא לאור: (2024-06-01)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
מאת: Jinyao Zhang, et al.
יצא לאור: (2021-12-01)

Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first‐line EGFR inhibitor resistance in lung cancer
מאת: Yen‐Ting Lin, et al.
יצא לאור: (2024-01-01)

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
מאת: Antonio Passaro, et al.
יצא לאור: (2021-07-01)

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
מאת: Helei Hou, et al.
יצא לאור: (2021-03-01)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
מאת: Xiaoyu Qian, et al.
יצא לאור: (2022-08-01)

Disease monitoring of epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA
מאת: Yan Li, et al.
יצא לאור: (2022-08-01)

Response to Osimertinib in a Patient with Non-Small Cell Lung Cancer and Two Uncommon EGFR Mutations
מאת: Christoforos Astaras, et al.
יצא לאור: (2020-03-01)

Smoking habit and chemo-radiotherapy and/or surgery affect the sensitivity of EGFR plasma test in non-small cell lung cancer
מאת: Vinh Thanh Tran, et al.
יצא לאור: (2020-08-01)

EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors
מאת: Anne C. Chiang, et al.
יצא לאור: (2020-04-01)

Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients
מאת: Obradovic Jasmina, et al.
יצא לאור: (2012-12-01)

Dynamic Evaluation of Circulating miRNA Profile in <i>EGFR</i>-Mutated NSCLC Patients Treated with EGFR-TKIs
מאת: Alessandro Leonetti, et al.
יצא לאור: (2021-06-01)

Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR‐mutated non‐small‐cell lung cancer: A case report
מאת: Meng Zhang, et al.
יצא לאור: (2022-05-01)

A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms
מאת: Joel Rivera-Concepcion, et al.
יצא לאור: (2024-03-01)

Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC
מאת: Meiyi XU, et al.
יצא לאור: (2023-02-01)

Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations
מאת: Xue-Wu Wei, MD, et al.
יצא לאור: (2022-07-01)

Design, Synthesis and Evaluation of Novel Cyclopropanesulfonamide Derivatives for the Treatment of EGFRC797S Mutation in Non-Small Cell Lung Cancer
מאת: Wang M, et al.
יצא לאור: (2025-02-01)

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study
מאת: Yuankai Shi, et al.
יצא לאור: (2023-01-01)

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms
מאת: Xin Liao, et al.
יצא לאור: (2024-10-01)

Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis
מאת: Haosheng Zheng, et al.
יצא לאור: (2024-01-01)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
מאת: Kaiwen Wang, PharmD, et al.
יצא לאור: (2023-08-01)